BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20622644)

  • 1. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
    Valakh V; Trombetta MG; Werts ED; Labban G; Khalid MK; Kaminsky A; Parda D
    Am J Clin Oncol; 2011 Jun; 34(3):245-8. PubMed ID: 20622644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA; Aksoy S; Zengin N; Altundag K
    J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Nishiyama K; Inaji H
    Anticancer Res; 2009 Nov; 29(11):4791-4. PubMed ID: 20032437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
    Nakatani K; Matsumoto M; Ue H; Nishioka A; Tanaka Y; Kodama H; Sasaguri S; Ogawa Y
    Breast Cancer; 2008; 15(4):321-3. PubMed ID: 18278432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
    Bremec T; Demsar J; Luzar B; Pavlović MD
    Dermatol Online J; 2009 Jul; 15(7):14. PubMed ID: 19903442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on adjuvant hormonal treatment of early breast cancer.
    Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
    Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
    Dixon JM
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
    Lycette JL; Luoh SW; Beer TM; Deloughery TG
    Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
    Azria D; Belkacemi Y; Romieu G; Gourgou S; Gutowski M; Zaman K; Moscardo CL; Lemanski C; Coelho M; Rosenstein B; Fenoglietto P; Crompton NE; Ozsahin M
    Lancet Oncol; 2010 Mar; 11(3):258-65. PubMed ID: 20138810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K; Man S; Geffen DB; Cohen Y
    Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
    Nabholtz JM; Reese DM
    Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
    [No Abstract]   [Full Text] [Related]  

  • 15. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
    Chino A; Okamoto H; Hirasaki Y; Ueda K; Ogawa K; Namiki T
    J Altern Complement Med; 2011 Nov; 17(11):1075-7. PubMed ID: 22070441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
    Watanabe N; Ootawa Y; Kodama K; Kaide A; Ootsuka N; Matsuoka J
    Breast Cancer; 2010 Oct; 17(4):247-53. PubMed ID: 19728030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
    Gnant M; Pfeiler G; Stöger H; Mlineritsch B; Fitzal F; Balic M; Kwasny W; Seifert M; Stierer M; Dubsky P; Greil R; Steger G; Samonigg H; Fesl C; Jakesz R
    Br J Cancer; 2013 Aug; 109(3):589-96. PubMed ID: 23868011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of adjuvant endocrine therapy for postoperative breast cancer patients].
    Doihara H; Ogasawara Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():563-7. PubMed ID: 17682212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.